INDIANAPOLIS, Aug. 16,
2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:
LLY) announced today that Marschall S.
Runge, M.D., Ph.D. is retiring from his role as an
independent director of Lilly's board of directors effective
Aug. 31, 2024.
Dr. Runge has served on Lilly's board since 2013, including as a
member of the board's Science and Technology Committee and Ethics
and Compliance Committee. He is currently the CEO of Michigan
Medicine, executive vice president for medical affairs at the
University of Michigan and dean of the
Medical School, and he plans to retire on June 30, 2025. Following retirement from these
leadership roles, Dr. Runge will remain on the Medical School
faculty as a professor engaged in providing health care and
education and will continue his passion for writing.
Dr. Runge has brought decades of experience to Lilly's board,
combining extensive knowledge as a physician and scientist with
expertise in health care faculty systems, biomedical research,
clinical trial design and patient safety. His practical experience
as a principal investigator has offered a research-driven
perspective on diabetes and obesity treatments.
"On behalf of the company and the entire board, I would like to
thank Marschall for his valuable service over the last decade,"
said David A. Ricks, Lilly chair and
CEO. "His expertise in science and medical affairs and his
patient-centric perspective have contributed to Lilly's efforts to
bring medicines to people around the world. We wish him well in his
ongoing efforts to advance health care and education."
About Lilly
Lilly is a medicine company turning science into healing to make
life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today our
medicines help more than 51 million people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges:
redefining diabetes care; treating obesity and curtailing its most
devastating long-term effects; advancing the fight against
Alzheimer's disease; providing solutions to some of the most
debilitating immune system disorders; and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow
us on Facebook, Instagram and LinkedIn. C-LLY
Refer
to:
|
Jordan Bishop;
jordan.bishop@lilly.com; 317-374-1878 (Media)
|
|
Joe
Fletcher; jfletcher@lilly.com; 317-296-2884
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-announces-retirement-of-marschall-s-runge-from-its-board-of-directors-302224526.html
SOURCE Eli Lilly and Company